Introduction {#s1}
============

Exacerbations of chronic obstructive pulmonary disease (COPD) are defined as a worsening of symptoms that result in the need for additional therapy \[[@C1]\]. Exacerbations of COPD impose negative impacts on lung function, emphysema, health-related quality of life and prognosis \[[@C2]--[@C4]\], and frequent exacerbations may cause progressive deterioration of COPD \[[@C5]\]. Although many studies have identified various clinical features or biomarkers associated with frequent exacerbations of COPD \[[@C6]--[@C9]\], the prediction and prevention of exacerbations of COPD are still challenging in clinical settings.

COPD is characterised by chronic inflammation in the airways as well as systemic inflammation. There is accumulating evidence that the adaptive immune response contributes to pathogenesis of COPD \[[@C10]--[@C12]\] and might have conflicting properties in both autoimmunity and self-protection. For example, it has been revealed that an anti-elastin autoantibody from B-cells is associated with emphysema \[[@C11], [@C13]\], and upregulated B-cell-related genes are correlated with emphysema severity \[[@C14]\]. Moreover, increased B-cell infiltration into the walls of small airways is correlated with decreased alveolar attachments in COPD \[[@C15]\]. On the other hand, secretory IgA deficiency in the small airways of COPD is associated with persistent inflammation, fibrotic remodelling and bacterial invasion \[[@C16]\]. In addition, a decrease in the mucosal nontypeable *Haemophilus influenzae*-specific antibody is associated with greater systemic and airway inflammation and a history of more frequent exacerbations in patients with COPD \[[@C17]\]. Moreover, there is remarkable evidence showing a significant relationship between decreased serum antibodies and frequent exacerbations of COPD, including our previous report \[[@C18], [@C19]\].

As most exacerbations are triggered by bacterial, viral, or combined infections \[[@C20]\], adaptive immunity by B-cells in COPD may serve for self-protection in preventing exacerbations. To confirm this hypothesis, we focused on free light chains (FLCs) for the assessment of adaptive immunity by B-cells in the present study. FLCs are excessive amounts of light chains relative to heavy chains that are produced during Ig synthesis and secreted into the blood \[[@C21]\] and have been used to estimate systemic B-cell activation in various inflammatory diseases \[[@C18], [@C19]\]. The aim of the present study was to elucidate whether low serum FLC, which is associated with decreased antibody production, would be a good marker to predict patients with COPD at a risk of future exacerbations.

Methods {#s2}
=======

Patients and study design {#s2a}
-------------------------

This was a prospective observational study conducted at Kyoto University. Outpatients with stable COPD were enrolled in the study between May 2013 and July 2014. The inclusion criteria were as follows: 1) a smoking history of 10 pack-years or more; 2) a diagnosis of COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria \[[@C22]\]; and 3) no COPD exacerbations within the past 4 weeks. The exclusion criteria were as follows: 1) α-1 anti-trypsin deficiency; 2) a combination of other respiratory diseases, such as bronchial asthma, interstitial pneumonia, or bronchiectasis; 3) a history of malignant neoplasms other than prostate cancer or endoscopically resected early cancer within the past 5 years; 4) a history of myeloproliferative disorders, including multiple myeloma and monoclonal gammopathy of undetermined significance; 5) comorbid liver cirrhosis; 6) comorbid end-stage renal disease undergoing maintenance dialysis; 7) comorbid autoimmune diseases or vasculitis; or 8) the use of oral corticosteroids or immunosuppressants. The ethics committee of Kyoto University approved this study (approval no. E1664), and all subjects provided written informed consent prior to participating.

Clinical examinations {#s2b}
---------------------

Symptoms were assessed using questionnaires such as the COPD assessment test (CAT) and the modified Medical Research Council (mMRC) dyspnoea scale. Information about comorbidities and past medical history was verified by interviews and medical records.

A pulmonary function test was performed following the inhalation of bronchodilators (400 µg of salbutamol and 80 μg of ipratropium). Spirometry, lung volume subdivisions, and the diffusion capacity of the lung for carbon monoxide (*D*~LCO~) were measured using a Chestac-65V instrument (Chest MI, Inc., Tokyo, Japan). The predicted pulmonary function values were calculated based on Japanese Respiratory Society equations \[[@C23]\].

Blood samples were collected at the time of the clinical examinations. Complete blood cell count, usual blood chemistry tests, and serum immunoglobulins (IgA, IgG, and IgM) were assessed. For the assessment of serum levels of FLCs, the serum was aliquoted and then stored at −80°C until analysis. For the assessment of lymphocyte fractions in peripheral blood mononuclear cells (PBMCs), PBMCs were isolated *via* gradient centrifugation method using Ficoll-Paque PLUS (GE Healthcare Japan, Tokyo, Japan) according to the manufacturer\'s manual and were frozen-stocked in Cell Banker 1 (Nippon Zenyaku Kogyo Co., Ltd., Fukushima, Japan) until analysis.

Measurement of FLCs {#s2c}
-------------------

Serum levels of FLCs were measured *via* an ELISA using a commercially available kit (Immunoglobulin Free Light Chains Kappa and Lambda Human ELISA; BioVendor, Brno, Czech Republic, catalogue no. RD194088100R) according to the manufacturer\'s protocol. The amount of kappa chains and lambda chains were measured, and the serum levels of combined free light chains (cFLCs) were presented as the summation of kappa and lambda values.

Flow cytometric analysis of peripheral blood mononuclear cells {#s2d}
--------------------------------------------------------------

PBMCs were stained with anti-CD138-PE (clone; MI15), anti-CD27-APC (M-T271), anti-CD3-BV510 (UCHT1), anti-CD4-APC-H7 (RPA-T4), anti-CD8-PerCP-Cy5.5 (RPA-T8) (BD Bioscience, NJ, USA), anti-CD19-FITC (HIB19) (eBioScience, CA, USA), and anti-IgD-PE-Cy7 (IA6--2) (BioLegend, CA, USA) after being stained with fixable viability stain 450 and (BD Bioscience) blocking with Fc block (BD Bioscience). Cells were analysed using a BD LSRFortessa (BD Bioscience), and data were analysed using FlowJo software (version 7.6.5, Tree Star, CA, USA Bioscience). Naïve B-cells were defined by CD19^+^CD27^−^IgD^+^, nonclass-switched memory B-cells by CD19 CD27^+^IgD^+^ and class-switched memory B-cells by CD19^+^CD27^+^IgD^−^.

Exacerbation criteria {#s2e}
---------------------

Exacerbations of COPD were prospectively identified using a symptom diary as in our previous study \[[@C8]\]. According to previous reports \[[@C8], [@C24]\], the definition of exacerbation was the worsening of symptoms as follows: two or more occurrences of three major symptoms (*i.e.*, increase in dyspnoea, sputum purulence and increased sputum volume) or any one major symptom with any one minor symptom (*i.e.*, increase in nasal discharge, wheezing, sore throat, cough or fever) for at least 2 consecutive days and requiring treatment with oral corticosteroids or antibiotics or both.

Statistical analysis {#s2f}
--------------------

The data pertaining to the continuous variables are expressed as the mean±[sd]{.smallcaps} unless otherwise specified. All statistical analyses were performed using JMP 10.0.2 (SAS Institute, Inc., NC, USA).

In the present study, patients were subdivided into subgroups using the cut-off value of the mean±[sd]{.smallcaps} value. Differences in clinical parameters between subgroups were analysed by the Kruskal--Wallis test for the continuous variables and the Chi-squared test for the categorical variables. The relationship between cFLC subgroups and the time to the first exacerbation of COPD was analysed using Kaplan--Meier curves and log-rank tests. Both univariate and multivariate Cox proportional hazards analyses were performed to investigate the relationship between the clinical parameters, including those in the cFLC subgroups, and the time to the first exacerbation of COPD. The results of the Cox proportional hazards analysis are depicted as hazard ratios (HRs) with 95% conﬁdence intervals (CIs). A p-value \<0.05 was considered statistically signiﬁcant.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

In total, 66 male patients with COPD agreed to be enrolled in the present prospective study ([Figure S1](http://openres.ersjournals.com/lookup/doi/10.1183/23120541.00288-2019.figures-only#fig-data-supplementary-materials)). During the initial examination, three patients were excluded, and in total, 63 patients were included in the follow-up study. During the follow-up, six patients developed malignancy, two patients died due to nonrespiratory diseases or the exacerbation of COPD, and four patients dropped out of the follow-up. Ultimately, 51 patients with COPD completed the 2-year follow-up. The characteristics of the study subjects (n=63) are provided in [table 1](#TB1){ref-type="table"}. The mean age of study participants was 72.8±8.1 years. The number of patients in each GOLD stage was 16 (25.4%), 26 (41.3%), 14 (22.2%) and 7 (11.1%) in GOLD stage I, II, III and IV, respectively, and the mean±[sd]{.smallcaps} value of the percentage of the predicted value of forced expiratory volume in 1 s (FEV~1~ % pred) was 61.4±21.9%. Regarding maintenance inhalation therapy, 27.0% (n=17) of patients were treated with long-acting muscarinic antagonist (LAMA) monotherapy, and 23.8% (n=15) were treated with a regimen including an inhaled corticosteroid (ICS). Additionally, 41.2% (n=26) were not treated with any maintenance inhalation therapy.

###### 

Patient characteristics (n=63)

  **Variable**                                                       
  ------------------------------------------------------------------ ----------------------------
  **Sex M/F n**                                                      63/0
  **Age years**                                                      72.8±8.1 (49--91)
  **Height cm**                                                      165.5±6.5 (149.0--178.0)
  **Weight kg**                                                      59.6±8.7 (39.3--83.0)
  **BMI kg·m^−2^**                                                   21.7±2.8 (15.6--27.9)
  **Smoking status former/current n**                                55/8
  **Smoking history pack-years**                                     67.6±39.1 (17.4--192)
  **Maintenance inhalation therapy**                                 
   LABA                                                              2 (3.2)
   LABA/ICS                                                          3 (4.8)
   LAMA                                                              17 (27.0)
   LAMA/LABA                                                         3 (4.8)
   LAMA/LABA/ICS                                                     12 (19.0)
   None                                                              26 (41.2)
  **Mucolytics n (%)**                                               15 (23.8)
  **Macrolides n (%)**                                               3 (4.8)
  **mMRC 0/1/2/3/4 n**                                               25/24/13/1/0
  **CAT points**                                                     11.2±7.4 (0--30)
  **Prior exacerbation yes/no n**                                    17/46
  **FEV~1~ L**                                                       1.66±0.68 (0.52--3.21)
  **FEV~1~ % pred**                                                  61.4±21.9 (20.0--112.0)
  **GOLD stage, I/II/III/IV n**                                      16/26/14/7
  **GOLD classification, A/B/C/D n**                                 24/28/6/5
  **FVC L**                                                          3.21±0.85 (1.46--5.66)
  **RV/TLC %**                                                       41.5±9.6 (24.6--67.8)
  ***D*~LCO~ mL·min^−1^mmHg^−1^**                                    12.67±4.63 (4.09--24.93)
  ***D*~LCO~ % pred**                                                53.0±17.9 (16.8--95.4)
  **WBC μL^-1^**                                                     6701±1864 (3000--12 800)
  **Neutrophils μL^-1^**                                             4145±1487 (1548--10 714)
  **Lymphocytes μL^-1^**                                             1864±653 (815--3722)
  **Eosinophils μL^-1^**                                             196±115 (0--628)
  **Eosinophils %**                                                  3.0±1.5 (0.0--6.1)
  **Cre mg·L^−1^**                                                   0.90±0.20 (0.58--1.87)
  **eGFR mL·min^−1^·1.73 m^−2^**                                     67.1±15.1 (27.3--100.8)
  **CRP mg·L^−1^**                                                   0.22±0.40 (0.0--2.5)
  **IgA mg·L^−1^**                                                   254.3±112.1 (96--713)
  **IgG mg·L^−1^**                                                   1286.6±267.3 (724--1801)
  **IgM mg·L^−1^**                                                   75.7±36.4 (17--192)
  **CD4^+^ T-cells % of lymphocytes**                                44.46±9.57 (22.98--67.50)
  **CD8^+^ T-cells % of lymphocytes**                                17.18±7.97 (3.95--42.55)
  **CD138^+^ plasma cells % of lymphocytes**                         0.20±0.26 (0.01--1.20)
  **CD19^+^ B-cells % of lymphocytes**                               5.81±3.09 (1.06--17.00)
  **CD19^+^CD27^−^IgD^+^ naïve B-cells % of B-cells**                67.33±14.83 (13.20--93.84)
  **CD19^+^CD27^+^IgD^+^ nonswitched memory B-cells % of B-cells**   7.87±4.79 (2.46--34.49)
  **CD19^+^CD27^+^IgD^−^ switched memory B-cells % of B-cells**      21.25±11.90 (3.31--61.93)
  **Kappa-FLC mg·L^−1^**                                             13.4±8.9 (0.6--51.5)
  **Lambda-FLC mg·L^−1^**                                            17.7±9.6 (0.8--75.3)
  **cFLC mg·L^−1^**                                                  31.1±14.7 (1.4--89.9)

Data are presented as mean±[sd]{.smallcaps} or n (%), unless otherwise stated. BMI: body mass index; LABA: long-acting β~2~-agonist; ICS: inhaled corticosteroid; LAMA: long-acting muscarinic antagonist; mMRC: modified British Medical Research Council scale; CAT: COPD assessment test; FEV~1~: forced expiratory volume in 1 s; % pred: % predicted; GOLD: Global Initiative for Chronic Obstructive Lung Disease; FVC: forced vital capacity; RV/TLC: residual volume/total lung capacity ratio; *D*~LCO~: diffusing capacity of the lung for carbon monoxide; WBC: white blood cell; Cre: creatinine; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein; FLC: free light chain; cFLC: combined free light chain.

Comparison between patients with low cFLC and those with high cFLC {#s3b}
------------------------------------------------------------------

The average cFLC was 31.1±14.7 mg·L^−1^ and ranged from 1.4 to 89.9 mg·L^−1^ ([table 1](#TB1){ref-type="table"} and [figure 1](#F1){ref-type="fig"}). The patients were subdivided into three subgroups using the cut-off value of the mean±[sd]{.smallcaps} value (cFLC=16.4 and 45.8 mg·L^−1^). Those with low cFLC (n=6) had significantly lower serum IgA (p=0.0091) and lower C-reactive protein (CRP) (p=0.043) levels. There was no significant difference in the proportion of patients with different medications, symptoms, pulmonary functions, eosinophil counts and lymphocyte fractions in PBMCs analysed by flow cytometry ([table 2](#TB2){ref-type="table"}).

![Distribution of combined free light chains (cFLCs) of the study subjects (n=63). The patients were subdivided into subgroups based on distribution of cFLC, and the mean±[sd]{.smallcaps} of the study subjects was used as the cut-off value. The bars indicate the mean value (± 95% CI) and [sd]{.smallcaps}.](00288-2019.01){#F1}

###### 

Comparison of pulmonary function and laboratory data between patient groups according to level of combined free light chain (cFLC)

  **Variable**                                                              **Low (n=6)**   **Normal (n=52)**   **High (n=5)**   **p-value**
  ------------------------------------------------------------------------ --------------- ------------------- ---------------- -------------
  **Age years**                                                               68.5±6.9          73.4±8.5           71.8±3.1          0.2
  **BMI kg·m^−2^**                                                            20.3±2.7          22.0±2.9           20.2±1.4          0.2
  **Smoking status, former/current**                                             6/0              7/45               4/1             0.4
  **Smoking history pack-years**                                              47.5±18.7         71.7±41.4          48.4±5.8          0.3
  **ICS use y/n**                                                                1/5              13/39              1/4             0.8
  **mMRC unit**                                                               0.67±0.82         0.87±0.77         0.80±1.30          0.8
  **CAT points**                                                              14.3±7.1          10.6±7.5           13.4±6.8          0.3
  **Prior exacerbation, y/n**                                                    0/6              17/35              0/5             0.1
  **Prior exacerbation n**                                                     0.0±0.0           0.4±0.7           0.0±0.0           0.2
  **FEV~1~ L**                                                                1.56±0.69         1.69±0.69         1.52±0.61          0.6
  **FEV~1~ % pred**                                                           55.6±22.3         63.0±22.2         52.4±19.0          0.2
  **FVC L**                                                                   3.34±1.00         3.20±0.84         3.05±0.98          0.6
  **RV/TLC %**                                                                40.9±14.6         41.6±9.2           41.0±9.7          0.7
  ***D*~LCO~ mL·min^−1^·mmHg^−1^**                                           13.02±6.32        12.97±4.45         9.15±3.66          0.7
  **WBC μL^-1^**                                                              6200±2256         6672±1686         7606±3137          0.8
  **Neutrophils µL^-1^**                                                      3853±1529         4067±1226         5308±3212          0.7
  **Lymphocytes µL^-1^**                                                      1727±750          1903±666           1625±343          0.7
  **Eosinophils μL^-1^**                                                       157±124           207±114            121±87           0.3
  **Eosinophils %**                                                           2.68±2.02         3.09±1.38         2.16±2.03          0.3
  **Cre mg·dL^−1^**                                                           0.81±0.11         0.91±0.21         0.92±0.13          0.4
  **eGFR mL·min^−1^·1.73 m^−2^**                                              74.4±10.5         66.6±15.8         63.6±10.4          0.3
  **CRP mg·dL^−1^**                                                           0.05±0.05         0.24±0.43         1.52±1.93         0.043
  **IgA mg·dL^−1^**                                                          152.6±47.0        263.8±107.2       260.0±168.9       0.0091
  **IgG mg·dL^−1^**                                                         1078.4±304.8      1315.0±263.9       1205.6±189.6        0.2
  **IgM mg·dL^−1^**                                                           66.6±37.0         77.0±37.1         71.6±32.9          0.6
  **CD4^+^ T-cells µL^-1^**                                                  756.4±289.9       858.0±392.2       796.8±188.0         0.9
  **CD8^+^ T-cells µL^-1^**                                                  294.9±341.7       337.9±217.9       305.7±137.7         0.3
  **CD138^+^ plasma cells count µL^-1^**                                      7.1±14.3           3.1±3.9           1.6±0.9           1.0
  **CD19^+^ B-cells count µL^-1^**                                           103.0±103.4       113.4±73.6         82.3±22.1          0.6
  **CD19^+^CD27^−^IgD^+^ naïve B-cells % of B-cells**                        67.71±6.11        67.23±15.59       68.05±13.79         1.0
  **CD19^+^CD27^+^IgD^+^ nonclass-switched memory B-cells % of B-cells**      8.68±3.48         7.82±5.10         7.23±2.34          0.6
  **CD19^+^CD27^+^IgD^−^ class-switched memory B-cells % of B-cells**        19.44±8.05        21.66±12.62        18.88±8.12         0.9

Data are presented as mean±[sd,]{.smallcaps} unless otherwise stated. BMI: body mass index; ICS: inhaled corticosteroid; mMRC: modified British Medical Research Council scale; CAT: COPD assessment test; FEV~1~: forced expiratory volume in 1 s; % pred: % predicted; GOLD: Global Initiative for Chronic Obstructive Lung Disease; FVC: forced vital capacity; RV/TLC: residual volume/total lung capacity ratio; *D*~LCO~: diffusing capacity of the lung for carbon monoxide; WBC: white blood cell; Cre: creatinine; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein.

Kaplan--Meier curve for the time to first exacerbation based on cFLC subgroups {#s3c}
------------------------------------------------------------------------------

Kaplan--Meier curves based on the cFLC subgroups are shown in [figure 2](#F2){ref-type="fig"}. The patients with low cFLC showed significantly shorter time to the first exacerbation of COPD than the other patients (p\<0.0001 by a log-rank test).

![Kaplan--Meier curve for the time to the first moderate/severe exacerbation based on combined free light chain (cFLC) subgroups. The patients with low cFLC (solid line, n=6) showed significantly shorter time to the first exacerbation of COPD than patients with normal (dashed line, n=52) or high cFLCs (dotted line, n=5) (p\<0.0001 by log-rank test).](00288-2019.02){#F2}

Cox proportional hazards analysis for the time to first exacerbation {#s3d}
--------------------------------------------------------------------

The relationships between the time to the first exacerbation and clinical parameters, including cFLC, were evaluated using univariate Cox proportional hazards analysis. A higher mMRC dyspnoea scale score (HR 1.65, p=0.02), a higher CAT score (HR 1.09, p=0.0006), higher number of previous exacerbations (HR 2.17, p=0.0048), a lower FEV~1~ % pred (HR 0.97, p\<0.0001), and a higher residual volume/total lung capacity ratio (RV/TLC) (HR 1.07, p=0.018) were significantly correlated with the time to the first exacerbation, but the eosinophil count was not correlated ([table 3](#TB3){ref-type="table"}). Although cFLC showed only a trend for risk for the first exacerbation (p=0.06); after dichotomising patients into subgroups, patients with low cFLC (\<16.36 mg·L^−1^) showed a significantly higher risk for exacerbation compared with patients with normal or high cFLC (HR 7.42, 95% CI 2.63--18.47, p=0.0005).

###### 

Univariate Cox proportional hazard analyses for the time to the first exacerbation of COPD

  **Variable**                             **HR**   **95% CI**    **p-value**
  --------------------------------------- -------- ------------- -------------
  **Age years**                             0.98    0.93--1.03        0.4
  **BMI, kg·m^−2^**                         0.89    0.77--1.02       0.096
  **mMRC unit**                             1.65    1.08--2.50       0.02
  **CAT points**                            1.09    1.04--1.14      0.0006
  **Prior exacerbation n**                  2.17    1.29--3.51      0.0048
  **FEV~1~ L**                              0.32    0.16--0.60      0.0002
  **FEV~1~ % pred**                         0.97    0.95--0.98     \<0.0001
  **RV/TLC %**                              1.07    1.02--1.11       0.018
  ***D*~LCO~ mL·min^−1^·mmHg^−1^**          0.94    0.87--1.02        0.2
  **WBC ×100·μL^-1^**                       0.99    0.97--1.01        0.5
  **Neutrophils ×100·μL^-1^**               0.99    0.96--1.01        0.4
  **Eosinophils ×10·μL^-1^**                0.99    0.95--1.03        0.6
  **Eosinophils %**                         0.94    0.72--1.20        0.6
  **eGFR mL·min^−1^·1.73 m^−2^**            1.01    0.99--1.04        0.4
  **CRP mg·dL^−1^**                         0.61    0.13--1.55        0.4
  **IgA mg·dL^−1^**                         0.99    0.99--1.00       0.34
  **cFLC mg·dL^−1^**                        0.97    0.94--1.00       0.06
  **cFLC low/normal *versus* high^\#^**     1.44    0.43--9.00       0.59
  **cFLC low *versus* normal/high^\#^**     7.42    2.63--18.47     0.0005

HR: hazard ratio; CI: confidence interval; BMI: body mass index; mMRC: modified British Medical Research Council scale; CAT: COPD assessment test; FEV~1~: forced expiratory volume in 1 s; % pred: % predicted; RV/TLC: residual volume/total lung capacity ratio; *D*~LCO~: diffusing capacity of the lung for carbon monoxide; WBC: white blood cell; eGFR: estimated glomerular filtration rate; CRP: C-reactive protein; cFLC: combined free light chain. ^\#^: Variable was used as the nominal variable.

In the multivariate Cox proportional hazards analyses, we analysed four models, including these established parameters after adjusting for age. In models 1 and 2, FEV~1~ % pred (HR 0.97, p=0.0012) was significantly correlated with the time to the first exacerbation. In models 3 and 4, cFLC was included as a continuous variable or categorised variable with regard to cFLC values, such as low *versus* normal/high cFLC.

Both models revealed that FEV~1~ % pred and cFLC were independently and significantly correlated with the time to the first exacerbation ([table 4](#TB4){ref-type="table"}). In particular, patients with low cFLC showed significant high risk for exacerbation compared with patients with normal/high cFLC (HR 6.74, p=0.0010) independently of FEV~1~ % pred.

###### 

Multivariate Cox proportional hazard analyses for the time to the first exacerbation of COPD

  **Variable**                           **Model 1**   **Model 2**   **Model 3**   **Model 4**                             
  ------------------------------------- ------------- ------------- ------------- ------------- -------- ---------- ------ ----------
  **Age years**                             0.95          0.044         0.95          0.040                 0.10              0.09
  **FEV~1~ % pred**                         0.97         0.0012         0.97         0.0027       0.96    \<0.0001   0.96   \<0.0001
  **Prior exacerbation n**                                 0.3          ^\#^          ^\#^        ^\#^                     
  **CAT unit**                              ^\#^                        0.07          ^\#^        ^\#^                     
  **cFLC mg·L^−1^**                         ^\#^          ^\#^          0.96          0.017       ^\#^                     
  **cFLC *versus* normal or high^¶^**       ^\#^          ^\#^          ^\#^          6.74       0.0010                    

HR: hazard ratio; mMRC: modified British Medical Research Council scale; FEV~1~ % pred: % predicted forced expiratory volume in 1 s; cFLC: combined free light chain. ^\#^: Variables not included in the model; ^¶^: variable was used as the nominal variable.

Discussion {#s4}
==========

In this study, we demonstrated that serum FLC might be a good biomarker for identification of patients at a risk of future exacerbations of COPD. While established variables associated with frequent exacerbations of COPD, such as the FEV~1~, symptom score, mMRC, and previous exacerbations were significant, multivariate Cox proportional hazards analyses interestingly revealed that low serum cFLC was independently associated with the time to first exacerbation (HR 6.74) in addition to the severity of airflow limitation (FEV~1~ % pred).

We could not confirm that eosinophils are associated with the risk of COPD exacerbation. Conflicting reports exist regarding whether an increased blood eosinophil level is associated with the risk of COPD exacerbation \[[@C25]--[@C28]\]. This discrepancy has been speculated to be due to the difference in COPD severity or the variation in eosinophil counts determined by a single measurement \[[@C28]\]. In the present study, no significant relationship was observed between eosinophil count and risk of COPD exacerbation. The mean±[sd]{.smallcaps} FEV~1~ % pred value in the current cohort was 61.4±21.9%, which is higher than the values in the Copenhagen General Population Study \[[@C25]\], COPD Gene study and ECLIPSE study \[[@C26]\]. The preserved lung function in the present cohort might contribute to the low exacerbation rate in the present study (0.66±0.93 per 2 years), which may explain why no association was observed between the eosinophil count and the risk of COPD exacerbation. The eosinophil count was measured only once in the present study. Approximately 40% of patients had eosinophil counts that oscillated across the cut-off value \[[@C27]\]. Because of the small cohort size in the present study, the oscillation in eosinophil counts might weaken the association between the eosinophil count and the exacerbation risk.

Most exacerbations of COPD are reported to be triggered by respiratory infections \[[@C20]\]. Immunoglobulins play a major role in humoral immunity against infections, and the secretary dysfunction of immunoglobulins may lead to various infectious diseases. Secretory IgA deficiency in the small airways of COPD or a decreased mucosal specific antibody have been reported to be associated with airway inflammation, airway remodelling or frequent exacerbations of COPD \[[@C18], [@C19]\]. Moreover, frequent exacerbations of COPD may be associated with an underlying antibody deficiency syndrome, and Ig replacement therapy is effective for reducing the rate of exacerbations of COPD \[[@C29]\]. Our findings are consistent with those from previous studies, because low cFLC may reflect secretory dysfunction in patients with COPD. Moreover, cFLC may be a more sensitive biomarker than IgA for predicting the risk of future exacerbations because we found only a trend and not a significant difference in serum IgA level. In fact, in a large cohort study, decreased but measurable subnormal serum IgA levels were demonstrated to be associated with a higher risk for exacerbations of COPD \[[@C30]\]. Moreover, if patients were dichotomised according to the mean−1×[sd]{.smallcaps} of the serum IgA value, the univariate analysis confirmed that patients with low serum IgA demonstrated a trend for a shorter time to the first exacerbation of COPD (p=0.087, data not shown). Therefore, these results might be due to the small sample size included in the present study.

During Ig synthesis, excess amounts of FLCs are produced and secreted into the blood \[[@C21]\]. High cFLC levels are observed in several autoimmune and inflammatory conditions, and cFLC levels are thought to reflect the systemic antibody production activity of B-cells \[[@C18], [@C19]\]. Not only IgA but also IgG subclass deficiency is reported to be associated with an increased risk of exacerbations of COPD \[[@C31]\]. Because cFLC has a shorter clearance time than IgA, IgG and IgM \[[@C32]\], cFLC might clearly reflect decreased antibody production.

However, the roles of FLCs in pathogenesis and pathophysiology are not yet well known. Some reports have shown different associations with pathophysiology and pathogenesis in COPD. B[raber]{.smallcaps} *et al*. \[[@C30]\] reported that patients with COPD showed higher levels of FLCs than control subjects. In addition, FLCs may exert biological functions, such as the inhibition of apoptosis \[[@C33]\] and the activation of neutrophils \[[@C30]\]. In the present study, the patients with low cFLC showed significantly lower CRP levels than those with high cFLC. This finding suggests that cFLC may be produced in the context of systemic inflammation in COPD. Systemic inflammation itself may lead to high risks of mortality, comorbidities or exacerbations in COPD patients \[[@C9], [@C34]--[@C36]\], and it is probable that extremely high FLC levels may be associated with the risk of mortality or comorbidities \[[@C37], [@C38]\]. It is possible that due to differences in the study population, we could not confirm such a biphasic association in COPD patients. In fact, patients with a high cFLC seem to be associated with a low risk for exacerbations of COPD ([figure 2](#F2){ref-type="fig"}). This might also be due to the small number of the study population. In addition, decreased antibody production might be more important than systemic inflammation in predicting the risk of exacerbations of COPD.

A previous report demonstrated that current smokers had higher percentages of class-switched memory B-cells than nonsmokers, irrespective of COPD \[[@C16], [@C29], [@C39]\]. We confirmed that among the study subjects, current smokers with COPD demonstrated a higher proportion of CD19^+^CD27^+^IgD^−^ class-switched memory B-cells than ex-smokers with COPD (current smoker *versus* ex-smoker; 30.5±14.4 *versus* 20.0±11.1, p=0.027). In addition, patients with COPD are reported to have a lower proportion of memory B-cells than healthy subjects \[[@C40]\]. These findings suggest that cigarette smoke might affect B-cell functions and that there might be unique alterations in patients with COPD compared to healthy subjects.

In the present study, cFLC was not associated with the number of plasma cells or the proportions of B-cells, such as naïve B-cells, nonclass-switched memory B-cells and class-switched memory B-cells ([table 2](#TB2){ref-type="table"}). This observation implies that the peripheral B-cell fraction cannot predict systemic antibody production in patients with COPD or that there might be dysfunctional antibody production in some patients with COPD. It is necessary to explore the exact role of the B-cell response or its involvement in COPD pathogenesis.

In order to further examine the cFLC value, we measured cFLC during an exacerbation of COPD in a limited number of patients. Compared to the stable condition, the cFLC value was significantly higher during exacerbation (data not shown), but the extent of cFLC value elevation varied among individuals. This variation may be informative in determining the mechanisms of systemic reactions and recovery from exacerbation. We did not conduct follow-up evaluations on these patients; therefore, the longitudinal changes of cFLC values are unknown. In addition, regarding reproducibility, only three patients underwent a two-point evaluation in the stable condition. They did not have any exacerbation during the interval (greater than 4 months), and their cFLC value had excellent reproducibility (interclass correlation coefficient=0.96).

From the results of the present study, we could conclude that low cFLC might be associated with the risk of a subsequent exacerbation. However, it is still necessary to conduct further longitudinal evaluation of cFLC values to identify "frequent" exacerbators.

There are several limitations to this study. First, the sample size was small. Female patients were excluded because of the small number of female patients in the cohort. In addition, approximately one-fifth of study subjects did not complete the follow-up, partially due to the relatively older age of the patients. However, the rates of and reasons for discontinuation of follow-up were similar among the cFLC subgroups, and we could confirm the significance of certain established variables, such as FEV~1~, previous exacerbation, and symptoms. We can speculate that our observation was sufficiently consistent with previous investigations. Second, this study cohort included a variety of patients with COPD, including patients with fairly mild disease. Even when we excluded the patients with mild disease whose FEV~1~/FVC was higher than the lower limit of normal, low cFLC was significantly associated with an increased risk for exacerbations of COPD. Third, there was no replication cohort and no preliminary information on the distribution of cFLC in normal subjects. To develop an appropriate cut-off value to predict future exacerbations in COPD, it will be necessary to refer to the distribution of cFLC in normal subjects as well. Further investigations using replication cohorts are required. Fourth, we did not evaluate the phenotype or triggers of exacerbation in the present study. In addition, a causal link between low cFLC and an increased risk for exacerbations of COPD was not directly demonstrated in the present study. There might be differences in the causes of exacerbation between the patients with low cFLC and those with normal cFLC. In addition, we could not include the influence of vaccination in the present analysis. In Japan, public support for vaccinations against pneumococcus or influenza virus in older people is available, but no data were provided regarding individual statuses. There are likely certain effects of these vaccinations in the prevention of exacerbation; at the same time, such vaccinations may change the immune profiles, such as those of IgG, IgA, and cFLC. These factors may be confounding influences in the present study. However, our data in this study also imply that patients with low cFLC might require intensive vaccinations.

Conclusions {#s5}
===========

Low serum cFLC, which is reported to reflect systemic antibody production, was associated with the risk for exacerbations of COPD. Decreased antibody production might be a specific feature related to higher risk for a future exacerbation of COPD within 2 years.
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